Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Among 886 patients with advanced renal-cell cancer, median progression-free survival was 13.8 months among those assigned to avelumab plus axitinib and 7.2 months among those assigned to sunitinib. Toxic effects of grade 3 or higher were similar in the two groups.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 380; no. 12; pp. 1103 - 1115
Main Authors Motzer, Robert J, Penkov, Konstantin, Haanen, John, Rini, Brian, Albiges, Laurence, Campbell, Matthew T, Venugopal, Balaji, Kollmannsberger, Christian, Negrier, Sylvie, Uemura, Motohide, Lee, Jae L, Vasiliev, Aleksandr, Miller, Wilson H, Gurney, Howard, Schmidinger, Manuela, Larkin, James, Atkins, Michael B, Bedke, Jens, Alekseev, Boris, Wang, Jing, Mariani, Mariangela, Robbins, Paul B, Chudnovsky, Aleksander, Fowst, Camilla, Hariharan, Subramanian, Huang, Bo, di Pietro, Alessandra, Choueiri, Toni K
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 21.03.2019
Subjects
Administration, Intravenous
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal - administration & dosage
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Apoptosis
Axitinib - administration & dosage
Axitinib - adverse effects
Body weight
Cancer therapies
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - mortality
Drug dosages
Evidence-based medicine
Female
Humans
Immunotherapy
Inhibitor drugs
Kidney cancer
Kidney Neoplasms - drug therapy
Kidney Neoplasms - mortality
Kinases
Male
Middle Aged
Monoclonal antibodies
Oncology
PD-L1 protein
Programmed Cell Death 1 Receptor - antagonists & inhibitors
Progression-Free Survival
Renal cell carcinoma
Single-Blind Method
Sunitinib - adverse effects
Sunitinib - therapeutic use
Survival Rate
Targeted cancer therapy
Tumors
Vascular endothelial growth factor
Germany
Online AccessGet full text

Cover

More Information
Summary:Among 886 patients with advanced renal-cell cancer, median progression-free survival was 13.8 months among those assigned to avelumab plus axitinib and 7.2 months among those assigned to sunitinib. Toxic effects of grade 3 or higher were similar in the two groups.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1816047